Daptomycin serum levels in critical patients undergoing continuous renal replacement

Journal of Chemotherapy

Volumn 24, Issue 5, 2012, Pages 253-256

  Venditti, Mario ^a   Falcone, Marco ^a   Russo, Alessandro ^a   Cassetta, Maria Iris ^b   Lappa, Angela ^c   Tritapepe, Luigi ^a   Fallani, Stefania ^b   Vullo, Vincenzo ^a   Novelli, Andrea ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Continuous renal replacement therapy; Daptomycin; Intensive care unit; Pharmacokinetic; Staphylococcal infections

Indexed keywords

DAPTOMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOODSTREAM INFECTION; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMODIALYSIS; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DAPTOMYCIN; FEMALE; HALF-LIFE; HEMODIAFILTRATION; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RENAL DIALYSIS; STREPTOCOCCAL INFECTIONS;

EID: 84866681858     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000033     Document Type: Article

References (9)

1. Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ. Acute renal failure in intensive care units Causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study French study group on acute renal failure. Crit Care Med. 1996;24:192-8.
2. Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, et al. Continuous renal replacement therapy: A worldwide practice survey: The beginning and ending supportive therapy for the kidney (BEST kidney) investigators. Intensive Care Med. 2007;33:1563-70.
3. Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009;37:2268-82.
4. DeRyke CA, Sutherland C, Zhang B, Nicolau DP, Kuti JL. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species. Antimicrob Agents Chemother. 2006;50:3529-34.
5. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker Inc.; 1982.
6. Vilay AM, Grio M, Depestel DD, Sowinski KM, Gao L, Heung M, et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med. 2011;39:19-25.
7. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004;48:2799-807.
8. Naka T, Haase M, Bellomo R. 'Super high-flux' or 'high cut-off' hemofiltration and hemodialysis. Contrib Nephrol. 2010;166:181-9.
9. Chakraborty A, Roy S, Loeffler J, Chaves RL. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother. 2009;64:151-8.